Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sulfapyridine is a synthetic **sulfonamide antibacterial agent**, historically known as M&B 693. It was one of the first effective antibiotics against bacterial pneumonia but has largely been replaced by safer alternatives due to its side effect profile. Its primary mechanism is **competitive inhibition of the enzyme dihydropteroate synthetase**, which blocks folic acid synthesis necessary for nucleic acid production in susceptible microorganisms. This action underlies its original use against various infections. Today, sulfapyridine's main clinical relevance is as a metabolite released from the prodrug **sulfasalazine**, which is widely prescribed for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel diseases. In this context, sulfapyridine exerts systemic anti-inflammatory effects by suppressing synthesis of inflammatory mediators and modulating immune cell infiltration at sites of inflammation. The term "Sulfapyridine-mediated immunomodulation" does not refer to a specific molecular target or receptor but rather describes an effect mediated by this small molecule drug/metabolite. Therefore: *It should not be considered a canonical therapeutic target like an enzyme or receptor.* The correct approach would be to reference either "Dihydropteroate synthase" if discussing its antibacterial action or describe it simply as "Sulfapyridine" when referring to its role within sulfasalazine therapy. Notable safety concerns include agranulocytosis risk—leading to discontinuation for most infectious indications—and potential urinary tract complications due to poor water solubility at certain pH levels. When administered via sulfasalazine therapy, additional risks include blood dyscrasias and male infertility.[1][3][6]
Competitive inhibition of bacterial dihydropteroate synthetase, blocking folic acid synthesis required for DNA/RNA production in bacteria As a component of sulfasalazine, contributes to systemic immunomodulatory/anti-inflammatory effects by suppressing inflammatory mediators and modulating cytokine secretion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sulfapyridine.